A Phase I, Randomized Open-label, 2-period, Parallel Arm Study To Assess The Immunogenicity Of Multiple Subcutaneous (SC) Doses Of "Filgrastim Hospira" (US) Or US-approved Neupogen(Registered) Reference Product In Healthy Volunteers

Trial Profile

A Phase I, Randomized Open-label, 2-period, Parallel Arm Study To Assess The Immunogenicity Of Multiple Subcutaneous (SC) Doses Of "Filgrastim Hospira" (US) Or US-approved Neupogen(Registered) Reference Product In Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Febrile neutropenia; Neutropenia
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 20 Feb 2017 Status changed from recruiting to completed.
    • 29 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 07 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top